# US 2021/0330694 A1 · Method for treating diastolic heart failure by inhibiting galectin-3

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330694 A1
- Document ID: US20210330694A1
- Status: Published application
- Kind: A1
- Application number: 17/367,957
- Filed: 2021-07-06
- Published: 2021-10-28
- Earliest claimed: 2012-12-20
- Assignees: Henry Ford Health System
- Applicants: Henry Ford Health System
- Inventors: Hani N. SABBAH
- Web page: https://patentgrep.com/patent/US20210330694A1

## CPC

- A61K 31/732: Pectin
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method for treating diastolic heart failure (heart failure with preserved ejection fraction (HFpEF)) in a subject in need thereof is provided including administering a therapeutically effective amount of a galectin-3 inhibitor to the subject.

## Claims

### Claim 1

A method for treating heart failure with preserved ejection fraction (HFpEF) in a subject in need thereof, the method comprising:
administering a therapeutically effective amount of a galectin-3 inhibitor to the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject has a left ventricular ejection fraction of greater than about 45%.

### Claim 3 (depends on 1)

The method of claim 1, wherein the subject has a left ventricle of reduced size compared with a control subject.

### Claim 4 (depends on 1)

The method of claim 1, wherein the subject has reduced left ventricular end-systolic and end-diastolic volumes compared with a control subject.

### Claim 5 (depends on 1)

The method of claim 1, wherein the galectin-3 inhibitor includes N-acetyl-D-lactosamine (LacNAc).

### Claim 6 (depends on 1)

The method of claim 1, wherein administering the galectin-3 inhibitor reduces interstitial fibrosis in the subject compared to before treatment.

### Claim 7 (depends on 6)

The method of claim 6, wherein interstitial fibrosis is reduced by at least about 50%.

### Claim 8 (depends on 1)

The method of claim 1, wherein administering the galectin-3 inhibitor increases left ventricular size in the subject compared to before treatment.

### Claim 9 (depends on 1)

The method of claim 1, wherein administering the galectin-3 inhibitor increases left ventricular end-systolic and end-diastolic volumes in the subject compared to before treatment.

### Claim 10 (depends on 1)

The method of claim 1, wherein administering the galectin-3 inhibitor increases left ventricular ejection fraction in the subject compared to before treatment.

### Claim 11 (depends on 1)

The method of claim 1, wherein administering the galectin-3 inhibitor increases E/A and Ei/Ai ratios in the subject compared to before treatment.

### Claim 12

A method for treating a subject exhibiting at least one symptom of heart failure with preserved ejection fraction (HFpEF), the method comprising:
administering a therapeutically effective amount of an inhibitor of galectin-3 to the subject.

### Claim 13 (depends on 12)

The method of claim 12, wherein the subject has a left ventricular ejection fraction of greater than about 45%.

### Claim 14 (depends on 12)

The method of claim 12, wherein the subject has a left ventricle of reduced size compared with a control subject.

### Claim 15 (depends on 12)

The method of claim 12, wherein the subject has reduced left ventricular end-systolic and end-diastolic volumes compared with a control subject.

### Claim 16 (depends on 12)

The method of claim 12, wherein the galectin-3 inhibitor includes N-acetyl-D-lactosamine (LacNAc).

### Claim 17 (depends on 12)

The method of claim 12, wherein the subject has increased interstitial fibrosis as compared to a control subject, and administering the galectin-3 inhibitor reduces interstitial fibrosis in the subject compared to before treatment.

### Claim 18 (depends on 12)

The method of claim 12, wherein administering the galectin-3 inhibitor increases left ventricular size in the subject compared to before treatment.

### Claim 19 (depends on 12)

The method of claim 12, wherein administering the galectin-3 inhibitor increases left ventricular end-systolic and end-diastolic volumes in the subject compared to before treatment.

### Claim 20

A method for treating diastolic heart failure in a subject with a left ventricular ejection fraction of greater than about 45%, the method comprising:
administering a therapeutically effective amount of N-acetyl-D-lactosamine (LacNAc) to the subject.
